Letter to the Editor
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Jan 26, 2025; 17(1): 100886
Published online Jan 26, 2025. doi: 10.4330/wjc.v17.i1.100886
Sodium-dependent glucose transporter 2 inhibitors improve heart function in patients with type 2 diabetes and heart failure
Yi-Fei Zhang, Yu-Xiang Liu, Wu-Xiao Yang
Yi-Fei Zhang, Wu-Xiao Yang, Department of Cardiology, Shanxi Provincial People's Hospital, Shanxi Medical University, Taiyuan 030012, Shanxi Province, China
Yu-Xiang Liu, Department of Nephrology, Shanxi Provincial People's Hospital, Shanxi Medical University, Taiyuan 030012, Shanxi Province, China
Co-corresponding authors: Yu-Xiang Liu and Wu-Xiao Yang.
Author contributions: Liu YX designed the overall concept and outline of the manuscript; Yang WX contributed to the design of the manuscript; Zhang YF and Liu YX contributed to the writing, and editing the manuscript, illustrations, and review of literature. Yang WX and Liu YX’s combined expertise in Cardiology and Nephrology was essential for addressing the multidisciplinary nature of the research topic. Their substantial and collaborative efforts in bringing this study to fruition are acknowledged by naming both as co-corresponding authors. The designation of two co-corresponding authors reflects the equal and complementary contributions made by both authors to this study. Dr. Yang WX was primarily responsible for the conceptualization, design, and supervision of the research project, ensuring its scientific rigor and clinical relevance. Dr. Liu YX, on the other hand, played a pivotal role in data acquisition, analysis, and manuscript preparation. Their joint expertise in Cardiology and Nephrology was essential for addressing the multidisciplinary nature of the research topic. By designating both as co-corresponding authors, we aim to acknowledge their substantial and collaborative efforts in bringing this study to fruition.
Conflict-of-interest statement: In the preparation of this work, the author employed the use of AI-assisted tools on the complete drafts of the article in order to enhance readability and language. The tools utilised were Grammarly, Quillbot Premium and Deepl Pro. Following the application of these tools, the author conducted a review and subsequent editing of the text as required, and accepts full responsibility for the content of the publication. The authors declare that they have no conflict of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wu-Xiao Yang, MD, Chief Doctor, Department of Cardiology, Shanxi Provincial People's Hospital, Shanxi Medical University, No. 29 Shuangtasi Street, Taiyuan 030012, Shanxi Province, China. 13753143192@163.com
Received: August 29, 2024
Revised: December 18, 2024
Accepted: December 27, 2024
Published online: January 26, 2025
Processing time: 144 Days and 23.8 Hours
Core Tip

Core Tip: Sodium-glucose cotransporter 2 inhibitor exert significant effects in patients with type 2 diabetes and heart failure (HF) through multiple mechanisms, including improving blood glucose control, promoting osmotic diuresis, reducing inflammation and oxidative stress, optimizing myocardial energy metabolism, regulating myocardial ion homeostasis, enhancing endothelial function, reducing sympathetic nervous system activity, and alleviating ventricular remodeling. These effects collectively improve cardiac function and prognosis, thereby reducing hospitalization rates and cardiovascular mortality in patients with various types of HF.